-
Aquestive Therapeutics NASDAQ:AQST Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.
Location: | Website: aquestive.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
359.2M
Cash
77.89M
Avg Qtr Burn
-8.553M
Short % of Float
12.44%
Insider Ownership
5.01%
Institutional Own.
55.36%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
ZUPLENZ (ondansetron) Details Nausea and vomiting | Approved Quarterly sales | |
KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) Details Parkinson’s disease (OFF Episodes / motor fluctuations) | Approved Quarterly sales | |
Exservan™ (riluzole) Oral Film Details Amyotrophic Lateral Sclerosis (ALS) | Approved Quarterly sales | |
SUBOXONE (buprenorphine/naloxone) Details Opioid addiction | Approved Quarterly sales | |
NDA Submission | ||
AQST-108 (epinephrine) Topical Gel Details Skin disease/disorder | Phase 1 Update | |
AQST-119 Details Erectile dysfunction
| Failed Discontinued |